rc 3095 has been researched along with Brain Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Battastini, AM; Braganhol, E; Brunetto, AL; Cechim, G; de Castro, CG; de Oliveira, MS; Lenz, G; Meurer, L; Roesler, R; Santos, DG; Schwarstmann, G; Schwartsmann, G | 1 |
Armatis, P; Groot, K; Kiaris, H; Schally, AV; Sun, B | 1 |
2 other study(ies) available for rc 3095 and Brain Neoplasms
Article | Year |
---|---|
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Dacarbazine; Exploratory Behavior; Flow Cytometry; Glioblastoma; Male; Peptide Fragments; Rats; Rats, Wistar; Receptors, Bombesin; Temozolomide | 2009 |
Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
Topics: Animals; Base Sequence; Bombesin; Brain Neoplasms; Cell Division; DNA Primers; Gastrin-Releasing Peptide; Glioblastoma; Humans; Mice; Mice, Nude; Peptide Fragments; Proto-Oncogene Proteins c-fos; RNA, Messenger | 1999 |